Serina Therapeutics SER 深 滬
等待開盤 10-28 09:30:00 美东时间
1.67
-0.040
-2.34%
華盛通- 最 高1.80
- 今 開1.38
- 成交量 17.20万股
- 最 低 1.38
- 昨 收 1.71
- 總市值 4241.88万
- 52周最高 4.448
- 市盈率 靜 --
- 換手率 0.68%
- 52周最低 1.22
- 委 比 5.56%
- 總股本 2540.05万
- 歷史最高 209.2615
- 量 比 4.79
- 振 幅 24.56%
- 歷史最低 1.22
- 每 手 1
- 風險率 0.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101.01%！Stifel上调ORIC Pharmaceuticals目标价至18美元，维持"买入"评级
今日重点评级关注：Stifel：维持ORIC Pharmaceuticals"买入"评级，目标价从14美元升至18美元；花旗：维持Liberty Energy"买入"评级，目标价从27.5美元升至28美元
10-27 12:30
BTIG Reiterates Buy on Serina Therapeutics, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates Serina Therapeutics (AMEX:SER) with a Buy and maintains $8 price target.
10-26 17:51
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
Serina Therapeutics, Inc. announced that its CEO, Steven Ledger, will present at Tribe Public’s webinar titled "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress" on September 24, 2026. The event will provide insights into the clinical progress of SER-252, a long-acting treatment for advanced Parkinson’s disease, developed using Serina’s proprietary POZ Platform™ technology. Participants can register at ...
09-23 20:18
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
BTIG Reiterates Buy on Serina Therapeutics, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates Serina Therapeutics (AMEX:SER) with a Buy and maintains $8 price target.
09-10 23:27
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Serina Therapeutics, a clinical-stage biotechnology company, announced that CEO Steve Ledger will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026, in New York. The presentation will be available on-demand starting September 14, 2026, at 7:00 a.m. ET. Serina is developing its proprietary POZ Platform™ technology to optimize drug candidates for neurological diseases and other conditions, with its lea...
09-10 20:05
Serina Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments
Serina Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 12,500,000 Shares Of Common Stock By Roth Principal Investments
08-25 05:32
Gannet BioChem To Support Development Activities For SER-252, Serina Therapeutics' Investigational Therapy For Advanced Parkinson's Disease
Gannet BioChem, a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE:SER), a clinical-stage biotechnology company advancing therapies enabled by its proprietary POZ Platform™ technology. Under the agreement, Gannet BioChem will...
06-30 21:08
